These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28833362)

  • 21. A Comparison of Vaginal and Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth.
    Frey HA; Finneran MM; Hade EM; Waickman C; Lynch CD; Iams JD; Landon MB
    Am J Perinatol; 2023 Nov; 40(15):1695-1703. PubMed ID: 34905780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Merlob P; Stahl B; Klinger G
    Reprod Toxicol; 2012 Jan; 33(1):15-9. PubMed ID: 22120850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eligibility, Utilization, and Effectiveness of 17-Alpha Hydroxyprogesterone Caproate in a Statewide Population-Based Cohort of Medicaid Enrollees.
    Wang X; Garcia SM; Kellom KS; Boelig RC; Matone M
    Am J Perinatol; 2023 Dec; 40(16):1770-1780. PubMed ID: 34784617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The use of progestatives for the prevention of spontaneous preterm birth].
    Azria E
    J Gynecol Obstet Biol Reprod (Paris); 2016 Dec; 45(10):1280-1298. PubMed ID: 27776845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-analysis of randomized controlled trials comparing 17α-hydroxyprogesterone caproate and vaginal progesterone for the prevention of recurrent spontaneous preterm delivery.
    Oler E; Eke AC; Hesson A
    Int J Gynaecol Obstet; 2017 Jul; 138(1):12-16. PubMed ID: 28369874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?
    Manuck TA
    Semin Perinatol; 2017 Dec; 41(8):461-467. PubMed ID: 28947068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Access to New Medications for Hepatitis C for Medicaid Members: A Retrospective Cohort Study.
    Clements KM; Clark RE; Lavitas P; Kunte P; Graham CS; O'Connell E; Lenz K; Jeffrey P
    J Manag Care Spec Pharm; 2016 Jun; 22(6):714-722b. PubMed ID: 27231798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaginal progesterone combined with cervical pessary: A chance for pregnancies at risk for preterm birth?
    Stricker N; Timmesfeld N; Kyvernitakis I; Goerges J; Arabin B
    Am J Obstet Gynecol; 2016 Jun; 214(6):739.e1-739.e10. PubMed ID: 26692180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery.
    Saghafi N; Khadem N; Mohajeri T; Shakeri MT
    J Obstet Gynaecol Res; 2011 Oct; 37(10):1342-5. PubMed ID: 21564406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?
    How HY; Barton JR; Istwan NB; Rhea DJ; Stanziano GJ
    Am J Obstet Gynecol; 2007 Sep; 197(3):260.e1-4. PubMed ID: 17826411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery.
    González-Quintero VH; Istwan NB; Rhea DJ; Smarkusky L; Hoffman MC; Stanziano GJ
    J Matern Fetal Neonatal Med; 2007 Mar; 20(3):249-52. PubMed ID: 17437227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity.
    Awwad J; Usta IM; Ghazeeri G; Yacoub N; Succar J; Hayek S; Saasouh W; Nassar AH
    BJOG; 2015 Jan; 122(1):71-9. PubMed ID: 25163819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 17-α hydroxyprogesterone caproate for the prevention of preterm birth.
    Gupta S; Roman AS
    Womens Health (Lond); 2012 Jan; 8(1):21-30. PubMed ID: 22171770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaginal progesterone, but not 17α-hydroxyprogesterone caproate, has antiinflammatory effects at the murine maternal-fetal interface.
    Furcron AE; Romero R; Plazyo O; Unkel R; Xu Y; Hassan SS; Chaemsaithong P; Mahajan A; Gomez-Lopez N
    Am J Obstet Gynecol; 2015 Dec; 213(6):846.e1-846.e19. PubMed ID: 26264823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Vaginal Progesterone Treatment With Prevention of Recurrent Preterm Birth.
    Nelson DB; Lafferty A; Venkatraman C; McDonald JG; Eckert KM; McIntire DD; Spong CY
    JAMA Netw Open; 2022 Oct; 5(10):e2237600. PubMed ID: 36315147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of 17α-hydroxyprogesterone caproate on preterm birth in women with an ultrasound-indicated cerclage.
    Rafael TJ; Mackeen AD; Berghella V
    Am J Perinatol; 2011 May; 28(5):389-94. PubMed ID: 21380984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of 17-α-hydroxyprogesterone caproate on preterm birth prevention in women with history-indicated cerclage.
    Mackeen AD; Rafael TJ; Zavodnick J; Berghella V
    Am J Perinatol; 2013 Oct; 30(9):755-8. PubMed ID: 23341330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?
    Hall NR
    Obstet Gynecol Clin North Am; 2011 Jun; 38(2):235-46, ix-x. PubMed ID: 21575799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double-blind multicentre trial.
    Serra V; Perales A; Meseguer J; Parrilla JJ; Lara C; Bellver J; Grifol R; Alcover I; Sala M; Martínez-Escoriza JC; Pellicer A
    BJOG; 2013 Jan; 120(1):50-7. PubMed ID: 22882759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
    Winer N; Bretelle F; Senat MV; Bohec C; Deruelle P; Perrotin F; Connan L; Vayssière C; Langer B; Capelle M; Azimi S; Porcher R; Rozenberg P;
    Am J Obstet Gynecol; 2015 Apr; 212(4):485.e1-485.e10. PubMed ID: 25448515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.